pamidronate has been researched along with Benign Neoplasms in 107 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 9.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| "We have conducted a randomized crossover comparative trial of a single-dose course of disodium (3-amino-1-hydroxypropylidene) bisphosphonate pentahydrate (pamidronate) and plicamycin in 48 patients with a first occurrence of tumor-related hypercalcemia." | 9.07 | Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. ( Senn, HJ; Thiébaud, D; Thürlimann, B; Waldburger, R, 1992) |
| "A single-dose infusion of 60 to 90 mg of pamidronate was highly effective and well tolerated and normalized corrected serum calcium in nearly all patients (61% to 100%) with hypercalcemia of malignancy." | 9.07 | Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. ( Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993) |
| "A 4-hour infusion of pamidronate disodium, 60 mg, was as safe and effective as a 24-hour infusion, and both were superior to saline alone in lowering corrected serum calcium concentrations in patients with cancer-associated hypercalcemia." | 9.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 9.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "Given the superior efficacy and comparable safety profile of zoledronic acid compared with pamidronate disodium, zoledronic acid is likely to become the treatment of choice for hypercalcemia of malignancy." | 8.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| "Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia." | 8.81 | Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. ( Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F, 2001) |
| "The primary objective was to compare the incidence of acute kidney injury (AKI) within 7 days of receiving pamidronate for the treatment of HCM with pre-existing renal dysfunction versus normal renal function at the time of pamidronate administration." | 8.02 | Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction. ( Norman, SJ; Reeves, DJ; Saum, LM, 2021) |
| "A time-motion study was performed by evaluating time and use of medical supply resources in the administration of zoledronic acid and pamidronate as palliative care of tumor-induced osteolysis within the clinical setting of three Italian oncology day-hospital sites." | 7.74 | [Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. ( Baldini, E; Berto, P; Cortesi, E; Dauria, G; Roila, F; Schivazappa, C, 2007) |
| "Pamidronate at a dose of 1 mg/kg is a safe and effective treatment for severe, refractory hypercalcemia of malignancy in children." | 7.70 | Use of pamidronate in the management of acute cancer-related hypercalcemia in children. ( Shende, A; Young, G, 1998) |
| "The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia." | 7.69 | Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. ( Ariyoshi, Y; Hasegawa, H; Niinomi, M; Oiso, Y; Sakiyama, N; Takano, T; Tomita, A; Yamamoto, M, 1994) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 7.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| "The effect of lowering ionized calcium on circulating parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) was assessed in twenty patients with hypercalcemia of malignancy following treatment with Pamidronate Disodium." | 7.68 | Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD). ( Grill, V; Ho, PW; Jerums, G; Martin, TJ; Murray, RM; Pitt, P; Potts, C; Santamaria, JD, 1992) |
| "Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days." | 7.68 | Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. ( Burckhardt, P; Jacquet, AF; Thiébaud, D, 1990) |
| "Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia." | 6.67 | [Pamidronate in the treatment of tumor-associated hypercalcemia]. ( Bosse, C; Fortelny, A; Gerber, E; Janisch, S; Lenzhofer, R; Marosi, C; Pecherstorfer, M; Rainer, H; Schratzberger, W; Wogritsch, C, 1991) |
| " infusion of pamidronate 90 mg in the treatment of malignant hypercalcemia." | 5.10 | Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. ( Atula, ST; Nevalainen, JI; Pylkkänen, LH; Tähtelä, RK, 2003) |
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 5.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| "Bisphosphonates are now the standard treatment for tumor-induced hypercalcemia (TIH), and pamidronate can normalize serum Ca in at least 90% of the patients treated for the first time." | 5.09 | Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. ( Body, JJ; Dumon, JC; Louviaux, I, 2000) |
| "A 4-hour infusion of pamidronate disodium, 60 mg, was as safe and effective as a 24-hour infusion, and both were superior to saline alone in lowering corrected serum calcium concentrations in patients with cancer-associated hypercalcemia." | 5.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 5.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "A single-dose infusion of 60 to 90 mg of pamidronate was highly effective and well tolerated and normalized corrected serum calcium in nearly all patients (61% to 100%) with hypercalcemia of malignancy." | 5.07 | Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. ( Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993) |
| "We have conducted a randomized crossover comparative trial of a single-dose course of disodium (3-amino-1-hydroxypropylidene) bisphosphonate pentahydrate (pamidronate) and plicamycin in 48 patients with a first occurrence of tumor-related hypercalcemia." | 5.07 | Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. ( Senn, HJ; Thiébaud, D; Thürlimann, B; Waldburger, R, 1992) |
| "Of 73 patients, 68 (93%) were treated with pamidronate or zoledronate; 69 (94%) patients suffered from malignant diseases, 3 (5%) had osteoporosis, and 1 (1%) had Paget's disease." | 4.83 | [Bisphosphonate-associated osteonecrosis of the jaw]. ( Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T, 2006) |
| "Given the superior efficacy and comparable safety profile of zoledronic acid compared with pamidronate disodium, zoledronic acid is likely to become the treatment of choice for hypercalcemia of malignancy." | 4.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| "Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia." | 4.81 | Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. ( Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F, 2001) |
| "Recent information on the pathophysiology and treatment of hypercalcemia of malignancy is reviewed, and the roles of two new agents, gallium nitrate and pamidronate, are discussed." | 4.78 | Update on the medical treatment of hypercalcemia of malignancy. ( Hall, TG; Schaiff, RA, 1993) |
| "The primary objective was to compare the incidence of acute kidney injury (AKI) within 7 days of receiving pamidronate for the treatment of HCM with pre-existing renal dysfunction versus normal renal function at the time of pamidronate administration." | 4.02 | Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction. ( Norman, SJ; Reeves, DJ; Saum, LM, 2021) |
| "A time-motion study was performed by evaluating time and use of medical supply resources in the administration of zoledronic acid and pamidronate as palliative care of tumor-induced osteolysis within the clinical setting of three Italian oncology day-hospital sites." | 3.74 | [Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. ( Baldini, E; Berto, P; Cortesi, E; Dauria, G; Roila, F; Schivazappa, C, 2007) |
| "Pamidronate at a dose of 1 mg/kg is a safe and effective treatment for severe, refractory hypercalcemia of malignancy in children." | 3.70 | Use of pamidronate in the management of acute cancer-related hypercalcemia in children. ( Shende, A; Young, G, 1998) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 3.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| "We reviewed our experience with pamidronate in 160 patients with tumour-induced hypercalcemia (TIH) persisting after rehydration, particularly the influence of the dose administered, the tumour type and the presence of bone metastatic involvement on the calcaemic and calciuric response to pamidronate therapy." | 3.69 | Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. ( Body, JJ; Dumon, JC, 1994) |
| "The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia." | 3.69 | Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. ( Ariyoshi, Y; Hasegawa, H; Niinomi, M; Oiso, Y; Sakiyama, N; Takano, T; Tomita, A; Yamamoto, M, 1994) |
| "Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days." | 3.68 | Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. ( Burckhardt, P; Jacquet, AF; Thiébaud, D, 1990) |
| "The effect of lowering ionized calcium on circulating parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) was assessed in twenty patients with hypercalcemia of malignancy following treatment with Pamidronate Disodium." | 3.68 | Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD). ( Grill, V; Ho, PW; Jerums, G; Martin, TJ; Murray, RM; Pitt, P; Potts, C; Santamaria, JD, 1992) |
| "Hypercalcemia of malignancy is associated with poor survival." | 2.82 | Hypercalcemia: A Review. ( Shane, E; Walker, MD, 2022) |
| "Twenty-five consecutive cancer patients with bone metastases treated monthly with disodium pamidronate infusion were evaluated prospectively for circulating levels of vascular endothelial growth factor (VEGF), gamma-IFN, interleukin (IL)-6, and IL-8 at different time points: just before and after 1, 2, and 7 days after pamidronate infusion." | 2.70 | Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. ( Avvisati, G; Battistoni, F; Denaro, V; Dicuonzo, G; Gavasci, M; Salerno, A; Santini, D; Tonini, G; Vincenzi, B, 2002) |
| "Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia." | 2.67 | [Pamidronate in the treatment of tumor-associated hypercalcemia]. ( Bosse, C; Fortelny, A; Gerber, E; Janisch, S; Lenzhofer, R; Marosi, C; Pecherstorfer, M; Rainer, H; Schratzberger, W; Wogritsch, C, 1991) |
| "Hypercalcemia of malignancy (HM) is one of the commonest metabolic complications associated with cancer." | 2.67 | Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. ( Wimalawansa, SJ, 1994) |
| "Thirty-nine patients with cancer-associated hypercalcaemia were randomly allocated to receive aminohydroxypropylidene diphosphonate (APD), mithramycin, or corticosteroids and salmon calcitonin." | 2.66 | Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. ( Boyle, IT; Cowan, RA; Dryburgh, FJ; Gardner, MD; Jenkins, AS; Ralston, SH, 1985) |
| "Thirty-three cancer patients remaining hypercalcemic after a 48-h rehydration period were included and monitored daily until normocalcemia or treatment failure was documented." | 2.66 | Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. ( Body, JJ; Borkowski, A; Magritte, A; Sculier, JP; Seraj, F, 1989) |
| "The results demonstrated that increased bone resorption is the major contributory factor and that inhibition with bisphosphonate normalizes the serum calcium concentration within five days in more than 90 percent of patients." | 2.66 | Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. ( Bijvoet, OL; Body, JJ; Elte, JW; Harinck, HI; Neijt, JP; Plantingh, AS; Sleeboom, HP; Wildiers, J, 1987) |
| "Indomethacin was effective in only one of five patients to whom it was given, and EHDP was effective also in only one of five patients." | 2.65 | Comparative study of available medical therapy for hypercalcemia of malignancy. ( Heath, DA; Mundy, GR; Wilkinson, R, 1983) |
| "Recurrent hypercalcemia is nevertheless difficult to control and antibodies against parathyroid hormone-related protein could be useful for that matter in selected patients who are not in the terminal stage of their disease." | 2.42 | Hypercalcemia of malignancy. ( Body, JJ, 2004) |
| "Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts." | 2.41 | Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002) |
| "Specific treatment of cancer remains essential to prevent TIH relapse." | 2.41 | [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001) |
| "Pamidronate (APD) is a potent inhibitor of bone resorption that is useful in the management of patients with osteolytic bone metastases from breast cancer or multiple myeloma, tumour-induced hypercalcaemia or Paget's disease of bone." | 2.40 | Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. ( Coukell, AJ; Markham, A, 1998) |
| "Basic guidelines for cancer pain treatment can be found in many different handbooks published in the last years." | 2.40 | [Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997) |
| "Treatment of cancer associated hypercalcaemia is based on an initial phase of volume repletion with isotonic saline, followed by drug treatment to inhibit bone resorption." | 2.39 | Pathogenesis and management of cancer associated hypercalcaemia. ( Ralston, SH, 1994) |
| "Haematologic malignancies and solid tumors are often complicated by the bone tissue destruction." | 2.39 | [Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. ( Kiełbiński, M, 1994) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ." | 1.35 | Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. ( Dodson, TB; Wessel, JH; Zavras, AI, 2008) |
| "Pamidronate was well tolerated apart from one case of multifactorial renal failure." | 1.33 | Hypercalcemia and childhood cancer: a 7-year experience. ( Aerts, I; Chevret, L; Doz, F; Fattet, S; Garabedian, M; Kerdudo, C; Michon, J; Orbach, D; Pacquement, H, 2005) |
| "Pamidronate is a second-generation bisphosphonate that undergoes negligible biodegradation and is eliminated exclusively by renal excretions." | 1.30 | Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. ( Berenson, JR; Knight, RD; Kowalski, MO; Lau, HS; Rosen, L; Seaman, JJ; Sioufi, A; Vescio, R; Woo, M, 1997) |
| "Breast cancers were more common in group N, squamous cell cancers predominated in group E (p < 0." | 1.29 | Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. ( Baumgartner, G; Blind, E; Pecherstorfer, M; Raue, F; Schilling, T; Ziegler, R; Zimmer-Roth, I, 1994) |
| " Patients received, on average, 30 mg less pamidronate than that given in the manufacturer's dosing schedule." | 1.29 | An audit of the management of malignant hypercalcaemia. ( Dodwell, DJ; Gerrard, GE; Overend, MA; Vail, A; Watters, J, 1996) |
| "In those patients in whom systemic anti-cancer therapy is available, treatment with APD improves survival, but in all other patients the primary aim of treatment should be symptom control." | 1.29 | Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). ( A'Hern, RP; Hardy, JR; Ling, PJ, 1995) |
| "Pamidronate has been demonstrated to be an effective agent in the treatment of cancer-associated hypercalcaemia." | 1.28 | A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. ( Boyle, IT; Cowan, RA; Dryburgh, FJ; Fraser, WD; Gallacher, SJ; Logue, FC; Ralston, SH, 1991) |
| "All three are useful for the treatment of hypercalcemia, but pamidronate seems to be the most effective." | 1.28 | Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991) |
| "Life expectancy is poor in cancer-associated hypercalcemia even in patients who are actively treated." | 1.28 | Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. ( Boyle, IT; Campbell, J; Gallacher, SJ; Patel, U; Ralston, SH, 1990) |
| "There were seven patients with breast cancer, eight with lung cancer, and ten with a variety of other cancers." | 1.28 | Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia. ( Cantwell, BM; Carmichael, J; Harris, AL; Mannix, KA, 1989) |
| "Eight patients with cancer associated hypercalcaemia were treated with the combination of aminohydroxypropylidene diphosphonate and salmon calcitonin for six days." | 1.27 | Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. ( Alzaid, AA; Boyle, IT; Gardner, MD; Ralston, SH, 1986) |
| " In order to establish a dose-response in humans, patients were divided into four groups receiving 30 mg, 45 mg, 60 mg, or 90 mg, respectively, as a 24-hour infusion." | 1.27 | Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. ( Burckhardt, P; Jacquet, AF; Jaeger, P; Thiébaud, D, 1988) |
| " AHPrBP was given as two-hour daily infusions for three days, and three different patients were treated at each of the six following dosage levels: 0." | 1.27 | Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. ( Body, JJ; Borkowski, A; Klastersky, J; Pot, M; Sculier, JP, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (22.43) | 18.7374 |
| 1990's | 47 (43.93) | 18.2507 |
| 2000's | 23 (21.50) | 29.6817 |
| 2010's | 11 (10.28) | 24.3611 |
| 2020's | 2 (1.87) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, MD | 1 |
| Shane, E | 1 |
| Norman, SJ | 1 |
| Reeves, DJ | 1 |
| Saum, LM | 1 |
| Owosho, AA | 1 |
| Liang, STY | 1 |
| Sax, AZ | 1 |
| Wu, K | 1 |
| Yom, SK | 1 |
| Huryn, JM | 1 |
| Estilo, CL | 1 |
| Haykal, T | 1 |
| Sundus, S | 1 |
| Bachuwa, G | 1 |
| Danish, R | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Wang, Z | 1 |
| Qiao, D | 1 |
| Lu, Y | 1 |
| Curtis, D | 1 |
| Wen, X | 1 |
| Yao, Y | 1 |
| Zhao, H | 1 |
| Wright, JD | 1 |
| Tergas, AI | 1 |
| Ananth, CV | 1 |
| Burke, WM | 1 |
| Hou, JY | 1 |
| Chen, L | 1 |
| Neugut, AI | 1 |
| Richards, CA | 1 |
| Hershman, DL | 1 |
| O'Ryan, FS | 1 |
| Khoury, S | 1 |
| Liao, W | 1 |
| Han, MM | 1 |
| Hui, RL | 1 |
| Baer, D | 1 |
| Martin, D | 1 |
| Liberty, D | 1 |
| Lo, JC | 1 |
| Weinstein, E | 1 |
| Arnold, RM | 1 |
| Nicolatou-Galitis, O | 1 |
| Papadopoulou, E | 1 |
| Sarri, T | 1 |
| Boziari, P | 1 |
| Karayianni, A | 1 |
| Kyrtsonis, MC | 1 |
| Repousis, P | 1 |
| Barbounis, V | 1 |
| Migliorati, CA | 1 |
| Legrand, SB | 1 |
| Goyne, H | 1 |
| Stone, PJ | 1 |
| Cannon, MJ | 1 |
| Jacobsen, C | 1 |
| Metzler, P | 1 |
| Rössle, M | 1 |
| Obwegeser, J | 1 |
| Zemann, W | 1 |
| Grätz, KW | 1 |
| Thumbigere-Math, V | 1 |
| Tu, L | 1 |
| Huckabay, S | 1 |
| Dudek, AZ | 1 |
| Lunos, S | 1 |
| Basi, DL | 1 |
| Hughes, PJ | 1 |
| Leach, JW | 1 |
| Swenson, KK | 1 |
| Gopalakrishnan, R | 1 |
| Major, P | 2 |
| Berenson, JR | 2 |
| Pecherstorfer, M | 6 |
| Steinhauer, EU | 1 |
| Rizzoli, R | 2 |
| Wetterwald, M | 1 |
| Bergström, B | 1 |
| Atula, ST | 1 |
| Tähtelä, RK | 1 |
| Nevalainen, JI | 1 |
| Pylkkänen, LH | 1 |
| Body, JJ | 9 |
| Kerdudo, C | 2 |
| Aerts, I | 2 |
| Fattet, S | 2 |
| Chevret, L | 2 |
| Pacquement, H | 2 |
| Doz, F | 2 |
| Michon, J | 2 |
| Garabedian, M | 2 |
| Orbach, D | 2 |
| Guarino, MJ | 1 |
| Hill, CE | 1 |
| Patel, K | 1 |
| Zarychanski, R | 1 |
| Elphee, E | 1 |
| Walton, P | 1 |
| Johnston, J | 1 |
| Abu-Id, MH | 2 |
| Açil, Y | 2 |
| Gottschalk, J | 2 |
| Kreusch, T | 2 |
| Schivazappa, C | 1 |
| Baldini, E | 1 |
| Cortesi, E | 1 |
| Dauria, G | 1 |
| Roila, F | 1 |
| Berto, P | 1 |
| Shenker, NG | 1 |
| Jawad, AS | 1 |
| Warnke, PH | 1 |
| Springer, I | 1 |
| Wiltfang, J | 1 |
| Russo, PA | 1 |
| Wessel, JH | 1 |
| Dodson, TB | 1 |
| Zavras, AI | 1 |
| Sleeboom, HP | 4 |
| Bijvoet, OL | 4 |
| van Oosterom, AT | 2 |
| Gleed, JH | 1 |
| O'Riordan, JL | 1 |
| Mundy, GR | 2 |
| Wilkinson, R | 1 |
| Heath, DA | 2 |
| van Breukelen, FJ | 1 |
| Frijlink, WB | 1 |
| Mulder, H | 1 |
| Ling, PJ | 1 |
| A'Hern, RP | 1 |
| Hardy, JR | 1 |
| Oiso, Y | 1 |
| Tomita, A | 1 |
| Hasegawa, H | 1 |
| Ariyoshi, Y | 1 |
| Niinomi, M | 1 |
| Yamamoto, M | 1 |
| Takano, T | 1 |
| Sakiyama, N | 1 |
| Anand, A | 1 |
| Anand, N | 1 |
| Walls, J | 1 |
| Ratcliffe, WA | 1 |
| Howell, A | 3 |
| Bundred, NJ | 1 |
| Budayr, AA | 1 |
| Zysset, E | 1 |
| Jenzer, A | 1 |
| Thiébaud, D | 9 |
| Ammann, P | 1 |
| Jaquet-Müller, F | 1 |
| Bonjour, JP | 1 |
| Gertz, B | 1 |
| Burckhardt, P | 7 |
| Kiełbiński, M | 1 |
| Gucalp, R | 2 |
| Theriault, R | 1 |
| Gill, I | 1 |
| Madajewicz, S | 1 |
| Chapman, R | 2 |
| Navari, R | 1 |
| Ahmann, F | 1 |
| Zelenakas, K | 1 |
| Heffernan, M | 1 |
| Knight, RD | 2 |
| Dumon, JC | 4 |
| Gurney, H | 2 |
| Grill, V | 2 |
| Martin, TJ | 2 |
| Wimalawansa, SJ | 1 |
| Schilling, T | 2 |
| Blind, E | 2 |
| Zimmer-Roth, I | 2 |
| Baumgartner, G | 1 |
| Ziegler, R | 2 |
| Raue, F | 2 |
| Thirion, M | 1 |
| Cleeren, A | 2 |
| Redalieu, E | 1 |
| Coleman, JM | 1 |
| Chan, K | 1 |
| Seaman, J | 2 |
| Degen, PH | 1 |
| Flesch, G | 1 |
| Brox, A | 1 |
| Batiste, G | 1 |
| Nussbaum, SR | 1 |
| Younger, J | 1 |
| Vandepol, CJ | 1 |
| Gagel, RF | 1 |
| Zubler, MA | 1 |
| Henderson, IC | 1 |
| Mallette, LE | 2 |
| Leidig, G | 1 |
| Hall, TG | 1 |
| Schaiff, RA | 1 |
| Rosenmund, A | 1 |
| Kinirons, MT | 1 |
| Ralston, SH | 12 |
| Gerrard, GE | 1 |
| Dodwell, DJ | 2 |
| Vail, A | 1 |
| Watters, J | 1 |
| Overend, MA | 1 |
| Machado, CE | 1 |
| Flombaum, CD | 1 |
| Sauty, A | 1 |
| Fioroni, P | 1 |
| Juillerat, L | 1 |
| Markert, M | 1 |
| Ludwig, H | 1 |
| Leuenberger, P | 1 |
| MacConnachie, AM | 1 |
| Rosen, L | 1 |
| Vescio, R | 1 |
| Lau, HS | 1 |
| Woo, M | 1 |
| Sioufi, A | 1 |
| Kowalski, MO | 2 |
| Seaman, JJ | 1 |
| De Conno, F | 1 |
| Polastri, D | 1 |
| Young, G | 1 |
| Shende, A | 1 |
| Coukell, AJ | 1 |
| Markham, A | 1 |
| Tezer Kutluk, M | 1 |
| Frye, D | 1 |
| Paule, B | 1 |
| Clerc, D | 1 |
| Brion, N | 1 |
| Louviaux, I | 1 |
| Lortholary, A | 2 |
| Hon, J | 1 |
| Abdi, E | 1 |
| Mills, G | 1 |
| Menssen, HD | 1 |
| Yunus, F | 1 |
| Bell, R | 1 |
| Body, J | 1 |
| Quebe-Fehling, E | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| Kato, Y | 1 |
| Tanaka, Y | 1 |
| Miyagawa, F | 1 |
| Yamashita, S | 1 |
| Minato, N | 1 |
| Santini, D | 1 |
| Vincenzi, B | 1 |
| Avvisati, G | 1 |
| Dicuonzo, G | 1 |
| Battistoni, F | 1 |
| Gavasci, M | 1 |
| Salerno, A | 1 |
| Denaro, V | 1 |
| Tonini, G | 1 |
| Ostenstad, B | 1 |
| Andersen, OK | 1 |
| Gallacher, SJ | 7 |
| Fraser, WD | 5 |
| Logue, FC | 3 |
| Dryburgh, FJ | 5 |
| Cowan, RA | 5 |
| Boyle, IT | 11 |
| Morton, AR | 2 |
| Daley-Yates, PT | 1 |
| Hoggarth, CR | 1 |
| Thürlimann, B | 1 |
| Waldburger, R | 1 |
| Senn, HJ | 1 |
| Seraj, F | 2 |
| Murray, RM | 1 |
| Ho, PW | 1 |
| Santamaria, JD | 1 |
| Pitt, P | 1 |
| Potts, C | 1 |
| Jerums, G | 1 |
| Ritch, P | 1 |
| Wiernik, PH | 1 |
| Sarma, PR | 1 |
| Keller, A | 1 |
| Richman, SP | 1 |
| Tauer, K | 1 |
| Neidhart, J | 1 |
| Siegel, R | 1 |
| Janisch, S | 1 |
| Marosi, C | 1 |
| Wogritsch, C | 1 |
| Bosse, C | 1 |
| Schratzberger, W | 1 |
| Gerber, E | 1 |
| Fortelny, A | 1 |
| Lenzhofer, R | 1 |
| Rainer, H | 1 |
| Coleman, RE | 1 |
| O'Reilly, DS | 1 |
| Beastall, GH | 1 |
| Patel, U | 3 |
| Campbell, J | 1 |
| Jacquet, AF | 4 |
| Sawyer, N | 1 |
| Newstead, C | 1 |
| Drummond, A | 1 |
| Cunningham, J | 1 |
| Kefford, R | 1 |
| Stuart-Harris, R | 1 |
| Magritte, A | 1 |
| Sculier, JP | 2 |
| Borkowski, A | 2 |
| Mannix, KA | 1 |
| Carmichael, J | 1 |
| Harris, AL | 2 |
| Cantwell, BM | 2 |
| Davis, JR | 1 |
| Gardner, MD | 4 |
| Jenkins, AS | 2 |
| McKillop, JH | 1 |
| Alzaid, AA | 2 |
| Cantrill, JA | 1 |
| Craig, AE | 1 |
| Davies, M | 1 |
| Anderson, DC | 1 |
| Warrell, RP | 1 |
| Harinck, HI | 1 |
| Plantingh, AS | 1 |
| Elte, JW | 1 |
| Wildiers, J | 1 |
| Neijt, JP | 1 |
| Jaeger, P | 3 |
| Pot, M | 1 |
| Klastersky, J | 1 |
| Portmann, L | 1 |
| Fuss, M | 1 |
| Karmali, R | 1 |
| Gillet, C | 1 |
| Corvilain, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study[NCT02480634] | Phase 4 | 280 participants (Anticipated) | Interventional | 2019-06-30 | Not yet recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for pamidronate and Benign Neoplasms
| Article | Year |
|---|---|
Hypercalcemia: A Review.
Topics: Calcium; Coma; COVID-19; Dehydration; Denosumab; Humans; Hypercalcemia; Hyperparathyroidism, Primary | 2022 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; | 2015 |
Modern management of malignant hypercalcemia.
Topics: Bone Density Conservation Agents; Calcitonin; Clinical Protocols; Diphosphonates; Fluid Therapy; Gal | 2011 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H | 2002 |
Hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Diphosphonates; Forecasting; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pa | 2004 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Im | 2006 |
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis].
Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteo | 1994 |
Update on the medical treatment of hypercalcemia of malignancy.
Topics: Animals; Antineoplastic Agents; Calcitonin; Diphosphonates; Etidronic Acid; Gallium; Humans; Hyperca | 1993 |
[Hypercalcemia as an emergency].
Topics: Calcitonin; Calcium; Diphosphonates; Emergencies; Fluid Therapy; Furosemide; Humans; Hypercalcemia; | 1993 |
Newer agents for the treatment of malignant hypercalcemia.
Topics: Diphosphonates; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1993 |
Pathogenesis and management of cancer associated hypercalcaemia.
Topics: Antineoplastic Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Diuretics; Etidronic Aci | 1994 |
Pamidronate (Aredia, Ciba) in malignant hypercalcaemia.
Topics: Diphosphonates; Drug Monitoring; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1997 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Neopl | 1998 |
Bisphosphonates as cancer drugs.
Topics: Antineoplastic Agents; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasm Proteins; Ne | 1999 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamid | 2000 |
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms | 2001 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog | 2001 |
27 trials available for pamidronate and Benign Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Human | 2003 |
Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
Topics: Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Infusio | 2003 |
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Fluid Therapy; Follow-Up Studies; Glomerular Filtratio | 1983 |
Comparative study of available medical therapy for hypercalcemia of malignancy.
Topics: Administration, Oral; Adult; Aged; Calcium; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 1983 |
Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Topics: Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney Tubul | 1994 |
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Topics: Adult; Breast Neoplasms; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; | 1994 |
Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle | 1994 |
Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions.
Topics: Adult; Aged; Bone Resorption; Chromatography, High Pressure Liquid; Diphosphonates; Female; Humans; | 1993 |
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Topics: Aged; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperca | 1993 |
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; | 1996 |
Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
Topics: Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Cytokines; Diphosphonates; Endothelial Gr | 2002 |
Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate; Plicamycin | 1992 |
Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Drug Administration Schedule; Female; Humans; Hyperc | 1992 |
Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Ne | 1992 |
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid; Fem | 1992 |
[Pamidronate in the treatment of tumor-associated hypercalcemia].
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hypercalcemia; Male; Middle Age | 1991 |
Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Topics: Calcium; Creatinine; Diphosphonates; Humans; Hypercalcemia; Kinetics; Neoplasms; Pamidronate | 1990 |
Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Topics: Administration, Oral; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration | 1989 |
Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Hematologic Test | 1989 |
Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, I | 1989 |
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Topics: Calcitonin; Calcium; Clinical Trials as Topic; Creatinine; Diphosphonates; Drug Therapy, Combination | 1985 |
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; Pamidronat | 1987 |
Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Topics: Calcium; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Infusions, Int | 1988 |
Treatment of hypercalcaemia of malignancy.
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Questions about clinical trials in hypercalcemia.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; | 1987 |
61 other studies available for pamidronate and Benign Neoplasms
| Article | Year |
|---|---|
Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction.
Topics: Acute Kidney Injury; Diphosphonates; Humans; Hypercalcemia; Indiana; Neoplasms; Pamidronate; Retrosp | 2021 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Ja | 2018 |
Primary isolated hepatosplenic sarcoidosis mimicking malignancy and causing symptomatic hypercalcaemia.
Topics: Aftercare; Aged; Bone Density Conservation Agents; Diagnosis, Differential; Female; Humans; Hypercal | 2019 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hyperc | 2015 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis | 2009 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neopla | 2010 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Co | 2011 |
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Cancer Vaccines; Clonal An | 2011 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents | 2013 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, | 2012 |
Hypercalcemia and childhood cancer: a 7-year experience.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercal | 2005 |
[Hypercalcemia and childhood cancer].
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercal | 2005 |
Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Osteonecrosis of the jaw associated with pamidronate therapy.
Topics: Actinomycosis; Antineoplastic Agents; Diphosphonates; Female; Humans; Male; Mandible; Neoplasms; Ost | 2006 |
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study].
Topics: Bone Density Conservation Agents; Costs and Cost Analysis; Diphosphonates; Humans; Imidazoles; Infus | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteopo | 2007 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphona | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Co | 2008 |
Hypercalcaemia due to malignancy. Role of the kidney and treatment.
Topics: Calcitonin; Calcium; Diphosphonates; Extracellular Space; Fluid Therapy; Glomerular Filtration Rate; | 1982 |
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyro | 1982 |
Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Ne | 1995 |
Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Topics: Aged; Calcium; Diphosphonates; Female; Homeostasis; Humans; Hypercalcemia; Infusions, Intravenous; K | 1994 |
Pamidronate for cancer-associated hypercalcemia.
Topics: Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1995 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; N | 1994 |
Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, | 1994 |
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Topics: Bone Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Electrolytes; Humans; Hypercalcemia; Kidney Tub | 1993 |
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia | 1994 |
Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; P | 1993 |
Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Topics: Adult; Aged; Dihydroxycholecalciferols; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle | 1993 |
An audit of the management of malignant hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Clinical Protocols; Diphosphonates; Female; Follow-Up Studi | 1996 |
Safety of pamidronate in patients with renal failure and hypercalcemia.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Creatinine; Diphosphonates; Female; Follow-Up Studies; Huma | 1996 |
Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
Topics: Aged; Aged, 80 and over; Area Under Curve; Diphosphonates; Female; Fever; Headache; Humans; Male; Me | 1997 |
Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Topics: Acute Disease; Adolescent; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hyperca | 1998 |
Use of bisphosphonates in hypercalcemia associated with childhood cancer.
Topics: Antineoplastic Agents; Child; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemi | 1999 |
Readers question whether drug increases side effects of chemotherapy.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Drug Monitoring; D | 1999 |
[Biosphonates in oncology].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain | 2000 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.
Topics: Cytotoxicity, Immunologic; Diphosphates; Diphosphonates; Humans; Immunotherapy; Interferon-gamma; Ly | 2001 |
Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Topics: Absorption; Calcium; Cyclic AMP; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidn | 1992 |
Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD).
Topics: Bone Resorption; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Middle Aged; Neopla | 1992 |
Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.
Topics: Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; Pamidronate; P | 1992 |
Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Topics: Calcium; Diphosphonates; Humans; Hypercalcemia; Neoplasm Proteins; Neoplasms; Pamidronate; Parathyro | 1992 |
Pamidronate.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Neoplasms; Ost | 1992 |
A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
Topics: Calcium; Creatinine; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1991 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp | 1991 |
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Topics: Aged; Calcium; Cyclic AMP; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Hypercalcemia | 1991 |
Use of bisphosphonates in hypercalcaemia due to malignancy.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1990 |
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Calcitonin; Diphosphonates; Dru | 1990 |
Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Topics: Aged; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Fluid Therapy; Humans; Hypercal | 1990 |
Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney; Neoplasms; Pa | 1989 |
Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Topics: Adult; Aged; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hypocalcemia; Infusio | 1989 |
Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Topics: Calcitonin; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate; Plicamycin | 1987 |
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Topics: Bone Resorption; Calcitonin; Calcium; Creatinine; Diphosphonates; Drug Therapy, Combination; Humans; | 1986 |
Dose-dependent effect of AHPrBP in malignant hypercalcemia: wishful thinking and facts.
Topics: Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Topics: Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hype | 1988 |
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Creatinine; Diphosphonates; Dose-Response Relationship, Dru | 1988 |
A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, I | 1986 |
Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Topics: Adult; Aged; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Male; | 1987 |
Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Topics: Administration, Oral; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Parenteral; Ma | 1986 |
[Treatment of hypercalcemia].
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1986 |